Mexico City, July 23rd, 2020.
The Federal Economic Competition Commission (FECC) made public today that it has initiated the investigation IO-001-2020 for the probable execution of relative monopolistic practices consisting in the establishment of exclusivity conditions related to sales or purchases in the market of manufacturing, distribution and marketing of medical oxygen and related services in the Mexican territory.
Regarding this investigation, the FECC explained that the medical oxygen is used as a medication for the treatment of respiratory conditions, for the treatment or prevention of blood oxygen shortages, in mechanical ventilation home services, in surgical interventions, as well as in studies to diagnose sleep disorders.
In this investigation, the FECC may request, from economic agents that participate or are related to the investigated market, that information in writing or statements be provided, or it may carry out inspections. In such cases, the Federal Economic Competition Law (FECL) sets out the obligation for economic agents to cooperate with the FECC and provide it with the requested information.
On the other hand, the publication of such investigation is for the purpose of providing any economic agent that may have an interest in the matter with the opportunity of contributing and providing any information it deems appropriate with relation to the investigated conduct or the circumstances which may violate the FECL. Therefore, any person or company, that considers that it may have been prejudiced in the investigated market will have the opportunity to provide its view to the FECC.
The Competition and Antitrust Practice of the firm will be pleased to provide any additional information on the topic.
S I N C E R E L Y,